1 hr ago
Geron Corporation Tanks As FDA Halts Development Of Blood Disorder Drug
Geron Announces IND Clinical Hold Affecting Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple Myeloma Menlo Park, Calif., March 12, 2014 - Geron Corporation GERN -65.91% announced today that the company has received verbal notice from the U.S. Food and Drug Administration that its Investigational New Drug application for ... (more)
Geron Corp. (GERN) Set to Announce Earnings on Wednesday
Geron Corp. is scheduled to be releasing its Q413 earnings data on Wednesday, March 12th.
Geron: A Biotech Stock With Potential For Long-Term Gains
Geron Corporation may be a good investment on the basis of its patented drug candidate for myelofibrosis .
Geron: Where Did The Shares Go?
This is a question relating to Geron that was begging to be answered since November 7, 2013.
Geron: Billion-Dollar Drugs And Possibility Of Accelerated Approval
Geron was initially focused on stem cell development but that business eventually faded.